Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapyQi Xu, Jieer Ying, Xiaoqing Xu et al.|Oncogenesis|2023Cited by 24
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of responseJingjing Li, Jieer Ying, Lei Chen et al.|Clinical and Translational Medicine|2020Cited by 24
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trialJingjing Li, Jieer Ying, Shurui Zhou et al.|Nature Communications|2025Cited by 12
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancersJiaojiao Ni, Jieer Ying, Chaoqun Li et al.|BMC Medicine|2025Cited by 7
Phase Ⅱ Study of Combined Sintilimab and Anlotinib with Gemcitabine plus Cisplatin in Advanced Biliary Tract Cancer: Efficacy, Safety and Optimize DoseJingjing Li, Jieer Ying, Shurui Zhou et al.|Research Square|2024Cited by 1